Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

被引:27
|
作者
Nelson, Winnie W. [1 ]
Wang, Li [2 ]
Baser, Onur [3 ,4 ]
Damaraju, Chandrasekharrao V. [5 ]
Schein, Jeffrey R. [1 ]
机构
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res HECOR, Raritan, NJ 08869 USA
[2] STATinMED Res, Plano, TX USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] MEF Univ, Istanbul, Turkey
[5] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
Atrial fibrillation; Clinical outcomes; International normalized ratio; USA; US veterans; Warfarin; RISK-FACTOR; ANTICOAGULATION CONTROL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANT; PREDICTING STROKE; INTENSITY; HOSPITALS; QUALITY;
D O I
10.1007/s11096-014-0038-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although efficacious in stroke prevention in non-valvular atrial fibrillation, many warfarin patients are sub-optimally managed. Objective To evaluate the association of international normalized ratio control and clinical outcomes among new warfarin patients with non-valvular atrial fibrillation. Setting Adult non-valvular atrial fibrillation patients (a parts per thousand yen18 years) initiating warfarin treatment were selected from the US Veterans Health Administration dataset between 10/2007 and 9/2012. Method Valid international normalized ratio values were examined from the warfarin initiation date through the earlier of the first clinical outcome, end of warfarin exposure or death. Each patient contributed multiple in-range and out-of-range time periods. Main outcome measure The relative risk ratios of clinical outcomes associated with international normalized ratio control were estimated. Results 34,346 patients were included for analysis. During the warfarin exposure period, the incidence of events per 100 person-years was highest when patients had international normalized ratio < 2:13.66 for acute coronary syndrome; 10.30 for ischemic stroke; 2.93 for transient ischemic attack; 1.81 for systemic embolism; and 4.55 for major bleeding. Poisson regression confirmed that during periods with international normalized ratio < 2, patients were at increased risk of developing acute coronary syndrome (relative risk ratio: 7.9; 95 % confidence interval 6.9-9.1), ischemic stroke (relative risk ratio: 7.6; 95 % confidence interval 6.5-8.9), transient ischemic attack (relative risk ratio: 8.2; 95 % confidence interval 6.1-11.2), systemic embolism (relative risk ratio: 6.3; 95 % confidence interval 4.4-8.9) and major bleeding (relative risk ratio: 2.6; 95 % confidence interval 2.2-3.0). During time periods with international normalized ratio > 3, patients had significantly increased risk of major bleeding (relative risk ratio: 1.5; 95 % confidence interval 1.2-2.0). Conclusion In a Veterans Health Administration non-valvular atrial fibrillation population, exposure to out-of-range international normalized ratio values was associated with significantly increased risk of adverse clinical outcomes.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [1] Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
    Winnie W. Nelson
    Li Wang
    Onur Baser
    Chandrasekharrao V. Damaraju
    Jeffrey R. Schein
    [J]. International Journal of Clinical Pharmacy, 2015, 37 : 53 - 59
  • [2] Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation
    Nelson, Winnie W.
    Wang, Li
    Baser, Onur
    Damaraju, C. V.
    Schein, Jeffrey R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (05) : 333 - 340
  • [3] Association of Out-of-Range International Normalized Ratio (INR) Values and Adverse Clinical Outcomes Among Newly Initiated Warfarin Patients With Non-Valvular Atrial Fibrillation and Comorbid Diabetes
    Nelson, Winnie W.
    Wang, Li
    Baser, Onur
    Damaraju, C. V.
    Schein, Jeffrey R.
    [J]. CIRCULATION, 2014, 130
  • [4] Warfarin in non-valvular atrial fibrillation
    Dalby, A. J.
    Wessels, P.
    Opie, L. H.
    [J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2013, 103 (12): : 901 - 904
  • [5] WARFARIN DISCONTINUATION AND STROKE RISK AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Wang, J.
    Qiao, Y.
    Spivey, C. A.
    Liu, X.
    Phatak, H.
    Mardekian, J.
    Claflin, A. B.
    Kachroo, S.
    Abdulsatter, Y.
    Parker, R. B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A8 - A9
  • [6] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    [J]. BLOOD, 2012, 120 (21)
  • [7] Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients
    Lip, G. Y. H.
    Keshishian, A.
    Li, X.
    Lee, T. C.
    Mardekian, J.
    Posner, N.
    Luo, X.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 774 - 775
  • [8] Evaluation of the Effectiveness of Warfarin Anticoagulation in Welsh Patients With Non-Valvular Atrial Fibrillation: The Sail Warfarin Out of Range Descriptors Study (SWORDS)
    Harris, Daniel
    Thayer, Daniel
    Brooks, Caroline
    Michael, Gravenor
    Hill, Nathan
    Murley, Geoff
    Vargas-Lopes, Francisca
    Wang, Ting
    Lister, Steven
    Halcox, Julian
    [J]. CIRCULATION, 2018, 138
  • [9] Identifying patients with non-valvular atrial fibrillation & poorly controlled INR on warfarin who are suitable to be switched to NOACs
    Ahmad, H. N.
    Van Staden, B.
    Haque, A.
    Khan, A.
    Gul, A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 41 - 41
  • [10] Key Factors That Lower Time in Therapeutic Range of Warfarin in Patients with Non-Valvular Atrial Fibrillation
    Tanaka, T.
    Ihara, M.
    Yamagami, H.
    Toyoda, K.
    Nagatsuka, K.
    [J]. CEREBROVASCULAR DISEASES, 2015, 40 : 70 - 70